{
  "id": 15601880,
  "title": "COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING",
  "url": "https://urgent.news/2026/10/19/cosciens-announces-new-corporate-presentation-and-provides-update-on",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T12:12:30.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/cosciens-announces-new-corporate-presentation-and-provides-update-on-convertible-debenture-offering"
  },
  "original_language": "en",
  "account": "COSCIENS has announced an update regarding its corporate presentation and a convertible debenture offering. The company's executives anticipate additional sales as part of the Offering, which will contribute to the pro forma market capitalization and cash position of COSCIENS. These forward-looking statements are given in accordance with the \"safe harbour\" provisions of applicable securities legislation.",
  "summary": "TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the publication of a new corporate presentation, now available on its website at www.cosciensbio.com. The presentation provides an overview of the Company and its operating subsidiaries, following the recent acquisition of Nualtis […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}